AQP4 and myasthenia gravis: In MG (5) and NMOSD (6, 7), autoantibodies against acetylcholine receptor and aquaporin-4 (AQP4), respectively, activate the complement system, causing neurological symptoms due to destruction of the nervous system by the terminal complement pathway.